OPC1 is an oligodendrocyte progenitor cell therapy that is currently in a Phase 1/2a multicenter clinical trial for acute spinal cord injuries (“SCI”), that has been partially funded by the California Institute for Regenerative Medicine. (“CIRM”).
Oligodendrocyte progenitor cells (OPCs) are naturally-occurring precursors to the cells which provide electrical insulation for nerve axons in the form of a myelin sheath. SCI occurs when the spinal cord is subjected to a severe crush or contusion injury and typically results in severe functional impairment, including limb paralysis, aberrant pain signaling, and loss of bladder and sexual function. Based on the multiple reparative properties associated with OPC1, we believe this candidate cell therapy product is ideally suited to treat neurological conditions such as SCI and other demyelination and demyelination disorders of the central nervous system.
OPC1 has received a regenerative medicine advanced therapy (RMAT) and Orphan Drug designations from the FDA, which include accelerated programs intended to facilitate the development and review process, including early interactions with FDA during clinical development and enhanced favorability for marketing approval.